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Abstract
Background: Somatostatin (SS)-binding sites have been demonstrated in human lymphoid tissues and
peripheral blood cells. However, not much is known with respect to the SS receptor subtype (sst)
expression pattern and the expression of SS itself in the immune system.
Objective: The aim of this study was to evaluate the mRNA expression of the five known sst (sst1 – 5) in
peripheral blood mononuclear cell (sub)populations. Moreover, the expression of the mRNAs encod-
ing SS and the SS-like peptide cortistatin (CST) in immune cell subsets was studied.
Methods: RT-PCR and quantitative PCR were performed to evaluate sst, SS and CST mRNA expression
in cells in the basal or activated state. Fluorescence-activated cell sorter (FACS) analysis using fluor-
escent SS was performed to visualize sst protein on cell membranes.
Results: B- and T-lymphocytes selectively expressed sst3 mRNA. sst3 expression in B-lymphocytes was
significantly lower compared with T-lymphocytes. Unstimulated, freshly isolated monocytes did not
express any sst mRNA. Upon activation, monocytes selectively expressed sst2 mRNA, whereas T-lym-
phocyte activation upregulated sst3 expression. sst2 mRNA expression on monocytes was confirmed
by FACS analysis. B- and T-lymphocytes did not express SS mRNA, while both cell types expressed CST
mRNA. CST mRNA expression was downregulated following T-lymphocyte activation.
Conclusion: We demonstrate for the first time unequivocally that human peripheral blood B- and T-lym-
phocytes selectively express sst3, whereas monocytes do not express sst. However, upon activation,
monocytes are induced to express sst2A. No expression of SS mRNA was detected in any cell type,
whereas all cell types expressed CST mRNA. The differential expression of sst and CST mRNA in lym-
phocytes and monocytes suggests a functional significance for the CST–sst interaction in immune
cells, but further studies should be performed to evaluate the significance of sst and CST in these cells.
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Introduction
Somatostatin (SS) is a small neuropeptide that is widely
distributed throughout the body and has numerous
functions. In the endocrine system it was originally
characterized as an inhibitor of growth hormone
secretion by the pituitary (1). SS also inhibits hormone
secretion from the gastrointestinal tract (2, 3), whereas
in the nervous system it functions as a neurotransmit-
ter (4). A growing body of evidence suggests a role for
SS in the immune system as well (5, 6). SS acts on its
target cells through specific G-protein coupled trans-
membrane receptors. Initially, these receptors were
identified as binding sites for radiolabelled ligands (7),
usually SS or the more stable synthetic analogue
octreotide. Later on, the genes of five different subtypes
were isolated. These SS receptor subtypes (sst) are being
characterized with respect to binding affinities for SS
analogues, coupling to effector systems for signal trans-
duction and tissue distribution of mRNA expression (8).
Although there are numerous studies demonstrating
the presence of SS-binding sites or effects of SS in lym-
phoid tissues, immune cells or lymphoid cell lines, the
data obtained so far do not present a clear view of
the function of SS in the immune system. A first step
towards understanding should be the elucidation of
the expression patterns of SS and its sst in the
immune system. In situ autoradiography and in vivo
scintigraphy have repeatedly demonstrated the pre-
sence of SS-binding sites in human lymphoid tissues
(9–16); however, it is not yet evident which sst are
expressed. It is also not clear how receptor expression
is regulated in the immune tissues and in immune
cells in the peripheral blood.
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Reports in the literature on this issue have been quite
equivocal. SS-binding sites in peripheral blood mono-
nuclear cells (PBMCs) were described by Bathena et al.
(17) in 1981. However, Hiruma et al. (18) were unable
to detect SS-binding sites on resting PBMCs; only after
mitogen activation were such binding sites detected.
Similarly, mRNA for sst subtype 2 (sst2) could barely
be detected in unstimulated human PBMCs, but was
readily detected after mitogen stimulation (19). In con-
trast, sst5 was reported to be responsible for growth
inhibition of PMBCs by SS analogues (20). Additionally,
several human lymphoid cell lines were shown to bear
SS-binding sites (21). Such cell lines can also express
mRNA for several sst (19, 22) and functionally respond
to SS or SS analogues (22 –24). These data, however,
yield by no means a conclusive notion of the expression
pattern of sst in human immune cells in vivo. Compari-
son with data obtained on PBMCs and other lymphoid
tissues from rat (25) or mouse (26) demonstrate
species-related differences and add to the confusion as
to which sst are expressed in human immune cells.
Therefore, in the present study we set out to clarify
the issue whether or not human PBMC subsets in the
circulation express sst and their natural ligand SS.
Moreover, we investigated the expression of the
mRNA encoding a recently discovered SS-like peptide,
cortistatin (CST), which we previously found to be
widely expressed in cells and tissues from the human
immune system (27). CST shows high structural resem-
blance to SS (28) and binds with high affinity to all five
sst (29). Accordingly, we isolated human PBMCs and
determined by RT-PCR whether SS, CST or sst were
expressed, and whether the expression pattern is
altered by mitogen activation. Moreover, we separated
the human PBMC cell fraction into subpopulations
and determined the expression patterns in T-lympho-
cytes, B-lymphocytes and monocytes. By quantitative
PCR (Q-PCR) we subsequently studied the regulation
of the sst and CST mRNA expression in PBMCs and
monocytes. To gain more insight into the cell-type-
specific expression of SS and its receptors in the
human immune system, a comparison was made
with the expression levels of sst in several other cell
lines and primary human immune cell types.
Materials and methods
Cells, media and reagents
PBMCs were isolated from 20–40 ml blood from eight
different healthy donors using Ficoll density-gradient
separation immediately after blood withdrawal. After
Ficoll separation, PBMCs were kept on ice to prevent
changes in mRNA expression during further treatment
of the cells. PBMCs or isolated subpopulations were
either used directly for mRNA analysis or cultured for
24 h at 37 8C in a 5% CO2 incubator in RPMI
medium supplemented with 10% heat-inactivated
fetal calf serum (Life Technologies), 105 U/l penicillin
and 1.25 mg/l Fungizone. PBMCs of three different
donors were used for further culture. As mitogenic
stimuli, we added either 2mg/ml phytohaemagglutinin
(PHA), 3mg/ml concanavalin A (ConA), 1mg/ml lipo-
polysaccharide (LPS) or 10mg/ml pokeweed mitogen
(PWM). After 24 h the cultured cells were harvested
for mRNA isolation as described below.
For fluorescent ligand-binding experiments (see
below) cell populations enriched for lymphocytes or
monocytes were used. Enrichment for lymphocytes
was achieved by allowing the monocytes among the
PBMCs to adhere to culture dishes and subsequently
collecting the non-adherent lymphocyte fraction for
further culturing. Monocytes were isolated by perform-
ing a Percoll density gradient following a standard
Ficoll density gradient as described previously (30).
Separation of PBMCs into subpopulations
Subpopulations of PBMCs were isolated by means of
magnetic beads coated with specific antibodies (Dynal
AS, Oslo, Norway). For T-lymphocyte isolation, beads
coated with CD2 or CD3 antibody were used, while
CD19-antibody-coated and CD14-antibody-coated
beads were used for B-lymphocyte and monocyte iso-
lation respectively. To distinguish between T-helper
cells and cytotoxic T-cells, beads coated with respectively
CD4 or CD8 antibodies were used. Isolation of cells was
performed following the manufacturer’s instructions.
After separation procedures, cells were either used for
RT-PCR or cultured for 24 h as described above.
RT-PCR
RT-PCR was performed as described previously (31).
Briefly, poly Aþ mRNA was isolated using Dynabeads
Oligo (dT)25 (Dynal) from cell samples. cDNA was syn-
thesized using the poly Aþ mRNA, which was eluted
from the beads in 40ml H2O for 10 min at 65 8C, using
Oligo (dT)12 – 18 Primer (Life Technologies). One-twenti-
eth of the cDNA library was used for each amplification
by PCR using primer sets specific for human SS, sst1 – 5,
CST and hypoxanthine phosphoribosyl transferase
(hprt) (see Table 1A) as a control. As positive controls
for SS, CST and hprt, cDNA of human brain RNA (Invi-
trogen, Groningen, The Netherlands) was used. As posi-
tive control for sst1 – 5, DNA of a BLCL-BSM cell line
(an EBV-transformed B-cell line) was used. The PCR
reaction was carried out in a DNA thermal cycler with
a heated lid (Applied Biosystems, Nieuwerkerk aan de
Ijssel, The Netherlands). After an initial denaturation
at 94 8C for 5 min, the samples were subjected to 40
cycles of denaturation at 94 8C for 1 min, annealing
for 2 min at 60 8C and extension for 1 min at 72 8C.
After a final extension for 10 min at 72 8C, 10ml
aliquots of the resulting PCR products were analysed
by electrophoresis on 1.5% agarose gels stained with
566 E G R Lichtenauer-Kaligis, V A S H Dalm and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004) 150
www.eje.org
ethidium bromide. The identity of the products was con-
firmed by direct sequencing using an ABI Prism 3100
Genetic Analyser (Applied Biosystems) according to
the manufacturer’s protocol (data not shown). Several
controls were included in the RT-PCR experiments. To
ascertain that no detectable genomic DNA was present
in the polyAþ mRNA preparation (since the sst genes
are intron-less), the cDNA reactions were also per-
formed without reverse transcriptase (RT) and amplified
with each primer pair. Amplification of the cDNA
samples with the hprt-specific primers served as positive
control for the quality of the cDNA. To exclude contami-
nation of the PCR reaction mixtures, the reactions were
also performed in the absence of the DNA template in
parallel with cDNA samples. No PCR products were
formed in the samples without RT or in the absence
of cDNA template (not shown). As a positive control
for the PCR reactions of the sst receptor subtypes,
0.1 –0.001mg human genomic DNA, representing
approximately 30 000 to 300 copies of sst template,
was amplified in parallel with the cDNA samples.
As a positive control for the PCR of the hprt, SS
and CST cDNA, aliquots of a cDNA sample known to
contain SS, CST and hprt mRNA were amplified,
because these primer pairs did enclose introns in the
genomic DNA.
Q-PCR
Q-PCR was performed employing a nuclease assay (32)
for real-time detection of amplification (33, 34) with an
ABI Prism 7700 Sequence Detection System (i.e. ther-
mal cycler and real-time fluorescence detector; Perkin
Elmer, Nieuwerkerk aan de Ijssel, The Netherlands).
New primer sets were designed for use in quantitative
PCR of sst2A, sst3, hprt and CST with accompanying
probes for the detection of the PCR products
(Table 1B). These were obtained from BioSource
(Nivelles, Belgium).
In each experiment, standard curves for each primer
set were included. Known amounts of genomic DNA
containing sst2A and sst3 or dilutions of a pool of hprt
or CST containing cDNAs were amplified (in duplicate
or triplicate) together with the unknown cDNA samples.
A standard curve was constructed by plotting the Ct
vs the logarithm of the starting quantity. With these
standard curves and the measured Ct of the unknown
cDNA samples the starting amounts in the cDNA
Table 1 Primers used for the RT-PCR and Q-PCR. The sequences of the primers for sst1 and sst4 are derived and adapted from (60),
for sst5 from (61), for CST from (62) and all other primers and probes were designed by use of the Primer3! software (http://
www-genome.wi.mit.edu/genome_software/other /primer3. html) and the appropriate GenBank entries.
Sequence (50 –30)a PCR product (bp)
A. RT-PCR
sst1 (forward) ATGGTGGCCCTCAAGGCCGG 318
sst1 (reverse) CGCGGTGGCGTAATAGTCAA
sst2A (forward)
b GCCAAGATGAAGACCATCAC 414
sst2A (reverse) GATGAACCCTGTGTACCAAGC
sst3 (forward) CCAACGTCTACATCCTCAACC 314
sst3 (reverse) TCCCGAGAAGACCACCAC
sst4 (forward) ATCTTCGCAGACACCAGACC 321
sst4 (reverse) ATCAAGGCTGGTCACGACGA
sst5 (forward) CGTCTTCATCATCTACACGG 226
sst5 (reverse) CCGTCTTCATCATCTACACGG
Somatostatin (forward) GATGCTGTCCTGCCGCCTCCAG 349
Somatostatin (reverse) ACAGGATGTGAAAGTCTTCCA
CST (forward) GCAAATTCGCTCTAAACACAGGA 173
CST (reverse) TTGGGAAGGAGGAGAGGAAAGAT
hprt (forward) CAGGACTGAACGTCTTGCTC 413
hprt (reverse) CAAATCCAACAAAGTCTGGC
B. Q-PCR
sst2A (forward) ATGCCAAGATGAAGACCATCAC 171
sst2A (reverse) TGAACTGATTGATGCCATCCA
sst2A (probe) TGGCTCTGGTCCACTGGCCCTTTG
sst3 (forward) CTGGGTAACTCGCTGGTCATCTA 86
sst3 (reverse) AGCGCCAGGTTGAGGATGTA
sst3 (probe) CGGCCAGCCCTTCAGTCACCAAC
CST (forward) GGAGAGAAGCTCCAGTCAGC 198
CST (reverse) GGTCCACTCAAACCACCAA
CST (probe) TATGCTCGCTGTCTCGGCCG
hprt (forward) TGCTTTCCTTGGTCAGGCAGTAT 109
hprt (reverse) TCAAATCCAACAAAGTCTGGCTTATATC
hprt (probe) CAAGCTTGCGACCTTGACCATCTTTGGA
a The position is given of the 50 nucleotide of the primer relative to the first nucleotide of the coding region in the cDNA sequence.
b The sst2 primers are specific for sst2A. In initial experiments we also included primers that amplify both sst2A and sst2B, but the sst2B specific product was
never found (unpublished results).
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samples were determined in duplicate or triplicate. To
correct for differences in the efficiency of RNA isolation
and cDNA synthesis the amounts of sst2A, sst3 and CST
were divided by the amount of hprt in a given cDNA
sample. Since the absolute copy number of hprt tem-
plates in the control cDNAs used for the hprt standard
curve is not known, the starting amounts are given in
arbitrary units.
Fluorescent SS binding
To detect SS-binding sites on PBMCs the fluorescein-
labelled SS analogue fluosomatostatin (Fluo-SS)
(Advanced Bioconcept, Montreal, Canada) was used.
Cells were washed with PBS containing 0.5% BSA
and incubated at room temperature with 50 nmol/l
Fluo-SS or with 50 nmol/l Fluo-SS and 5000 nmol/l
D-trp8-SS14. After 30 min incubation an appropriate
dilution of phycoerythrin (PE)-labelled CD3, CD19
(Becton Dickinson, Erembodegem, Belgium) or CD14
antibodies (Beckman Coulter, Mijdrecht, The Nether-
lands) was added. Following a further 15 min incu-
bation the cells were washed, resuspended in PBS
containing 0.5% BSA and 20 mmol/l sodium azide
and analysed on a fluorescence-activated cell sorter
(FACS) (FACScan Cytometer; Becton Dickinson). As a
positive control for ligand binding, a cell line stably
transfected with sst2A was used.
Results
sst, SS and CST mRNA in PBMCs
To determine whether or not sst mRNA is expressed in
the PBMC cell fraction of circulating blood we started
isolation of the cells immediately after blood withdrawal
and were able to lyse the cells within 2 h. This guaran-
tees that the RNA expression pattern of the studied cells
resembles that of the live cells in the circulation as clo-
sely as possible. In doing so, we consistently found
expression of sst3 mRNA in all eight PBMC samples
by RT-PCR (Fig. 1). In some experiments a very weak
sst2A PCR product could be detected as well, but only
after 40 cycles when the detection limit for sst2A was
better than 1% of the population. None of the other
sst subtypes could be detected, nor mRNA for SS itself
(Table 2). However, we detected the mRNA for CST in
all cell samples (Table 2). In some experiments also a
PCR specific for sst2B was performed, but this subtype
was never detected (results not shown).
After culturing the eight isolated PBMC preparations
for 24 h in medium alone or in medium containing the
mitogenic agents PHA, ConA, PWM or LPS the expre-
ssion of sst2A mRNA was clearly induced (Fig. 1;
Table 2). The expression pattern of the other sst and
of SS remained unchanged (sst3 detectable, others
not, no SS).
Expression in T-lymphocytes, B-lymphocytes
and monocytes
To determine in which cell-type sst2A and sst3 receptors
are expressed, we separated the PBMC cell population
into its main subpopulations of T-lymphocytes, B-lym-
phocytes and monocytes by use of paramagnetic
beads coated with appropriate antibody. The isolated
cell populations were subsequently assayed by RT-PCR
(Fig. 2; Table 2). The results demonstrated that sst3
was expressed by CD3þ T-lymphocytes and by CD19þ
B-lymphocytes, but not by CD14þ monocytes. None
of the other sst or SS was expressed in these three sub-
populations, whereas the expression of CST mRNA was
found in all subpopulations evaluated (Table 2). Iso-
lation of T-lymphocytes by CD2-antibody-coated
instead of CD3-antibody-coated beads yielded similar
results. Culturing the isolated cell populations during
Figure 1 RT-PCR analysis of SS (som) and SS receptor
expression in naı¨ve and cultured PBMCs. PBMCs were assayed
for expression of mRNA immediately after isolation (naı¨ve) or
after 24 h culturing in culture medium alone (medium) or with the
addition of PHA, LPS, PWM or ConA. Control DNA samples con-
tained either cDNA (lanes c) from a control cell line known to
express hprt and SS mRNA, or different amounts of genomic
DNA (lanes 1021, 1022 and 1023mg) comprising 30 000, 3000
and 300 copies of sst genes respectively. All mock-reverse-tran-
scribed samples and all controls with no added template showed
no PCR products and none of the samples expressed sst4 or sst5
(not shown). Marker lanes (M) contain a 100 bp DNA ladder. This
Figure shows mRNA expression of one healthy donor as repre-
sentative of the eight donors used.
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24 h in medium alone or in medium containing ConA,
PWM or LPS induced sst2A in the monocyte fraction
only (Fig. 2). sst3 expression remained confined to T-
and B-lymphocytes, whereas the other sst and SS
were still undetected in all cell populations studied
(Fig. 2; Table 2). In the same way we determined the
expression pattern of unstimulated and ConA-stimu-
lated CD4þ and CD8þ T-lymphocytes and found in all
populations a selective expression of sst3 mRNA (data
not shown).
Quantification of sst2A, sst3 and CST mRNA
expression
To quantify the induction of sst2A mRNA after acti-
vation we performed a Q-PCR on cDNA of PBMCs
from four donors and on purified monocytes from two
donors before and after activation (24 h culturing in
medium). The sst2A and sst3 mRNA expression (in arbi-
trary units) corrected for the amount of hprt in the
different samples is shown in Fig. 3. In all PBMC
samples there was a significant induction of sst2A
mRNA levels after activation. In the monocyte popu-
lations purified from two of the donors the induction
was even larger. In three of the four donors also the
sst3 expression in PBMCs was slightly increased after
activation. Among the donors the expression levels of
both sst2A (after activation) and sst3 showed a broad
range.
Since the very low amount of sst2A mRNA in naı¨ve
cells cannot be determined with the same accuracy as
the higher copy numbers, it is difficult to express the
induction as a fold of the level in naı¨ve cells. However,
the sst2A copy number obtained after RNA isolation
and cDNA synthesis per million PBMCs increased
from approximately 1000 (or less) to 25 000 –
150 000. In contrast, the number of sst3 copies
obtained per million naı¨ve PBMCs was approximately
7000 –15 000. From three donors of PBMCs, T- and
B-lymphocytes were isolated and Q-PCR was performed
to quantify the expression of sst2A, sst3 and CST mRNA
in these cell subsets as well.
As already demonstrated by RT-PCR, T- and B-lym-
phocytes were found to express sst3 selectively. After
24 h of culture, expression of sst3 mRNA was upregu-
lated approximately 1.5-fold in T-lymphocytes. After a
24 h incubation with PHA, sst3 mRNA levels were
upregulated approximately 2.5-fold when compared
with control cells (Fig. 4). In B-lymphocytes, on the
other hand, we were not able to detect expression of
sst3 mRNA by Q-PCR, even after culture and stimu-
lation with PHA (data not shown). This is probably
due to very low expression levels of sst3 in B-lympho-
cytes and probably the conditions or primers for
RT-PCR are more sensitive to detect these low levels.
For comparison we determined the expression levels
of sst2A and sst3 in several other normal human
Table 2 Expression of somatostatin receptor subtype, CST and
SS mRNA in PBMCs (n ¼ 8), purified peripheral blood T-
lymphocytes (n ¼ 4), B-lymphocytes (n ¼ 4) and monocytes
(n ¼ 4).
sst1 sst2A sst3 sst4 sst5 CST SS
PBMCs
0 h 2 2 þ 2 2 þ 2
24 h medium 2 þ þ 2 2 þ 2
24 h PHA 2 þ þ 2 2 þ 2
24 h ConA 2 þ þ 2 2 ni 2
24 h PWM 2 þ þ 2 2 ni 2
24 h LPS 2 þ þ 2 2 ni 2
T-lymphocytes (CD3þ)
0 h 2 2 þ 2 2 þ 2
24 h medium 2 2 þ 2 2 þ 2
24 h ConA 2 2 þ 2 2 þ 2
B-lymphocytes (CD19þ)
0 h 2 2 þ 2 2 þ 2
24 h medium 2 2 þ 2 2 þ 2
24 h PWM 2 2 þ 2 2 þ 2
Monocytes (CD14þ)
0 h 2 2 2 2 2 þ 2
24 h medium 2 þ 2 2 2 þ 2
24 h LPS 2 þ 2 2 2 þ 2
ni ¼ not investigated.
Figure 2 RT-PCR analysis of sst2 and sst3 expression in naı¨ve and cultured purified T-lymphocytes, monocytes and B-lymphocytes.
Cells were assayed for expression of mRNA immediately after isolation (naı¨ve) or after 24 h culturing in culture medium with the addition
of ConA, LPS or PWM. Control DNA samples contained either cDNA from a control cell line (lane c) or different amounts of genomic
DNA (lanes 1021, 1022 and 1023mg) comprising 30 000, 3000 and 300 copies of sst genes respectively. All mock-reverse-transcribed
samples and all controls with no added template showed no PCR products and none of the samples expressed sst1, sst4 or sst5 (not
shown). Marker lanes (M) contain a 100 bp DNA ladder. Results represent an example of the findings in cell separations from four
individual healthy donors.
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immune cells, in leukaemic cells and in lymphoid cell
lines (Fig. 5). In freshly dispersed normal human thy-
mocytes the sst3 expression levels were similar to the
levels found in PBMCs, whereas there was more sst2A
mRNA than in naı¨ve PBMCs. In normal human bone
marrow cells, the expression of sst2A was much
higher. Although the expression level of sst2A in
human haematological tumour cells is highly variable,
sst2A was present in both tumour cell populations stu-
died. sst3 was just detectable in normal bone marrow
Figure 3 Quantitative PCR analysis of sst2A and sst3 mRNA expression in human immune cells. sst2A and sst3 levels were corrected
for the amount of hprt detected in each sample and are given in arbitrary units. PBMCs from four donors, monocytes from two donors
and T- lymphocytes from three donors were analysed in naı¨ve (2) and activated (þ ) states. Hatched bars represent sst2A mRNA, white
bars represent sst3 mRNA. nd ¼ not detected.
570 E G R Lichtenauer-Kaligis, V A S H Dalm and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004) 150
www.eje.org
cells and tumour cells studied. In immortalized T- and
B-cell lines, sst2A and sst3 were also both present.
However, these cell lines contained approximately
10–20 times more hprt mRNA per cell than naı¨ve
PBMCs. Therefore the absolute numbers of sst2A and
sst3 mRNA copies obtained per million cells were
much higher than in PBMCs. In established T-cell
lines the amount of sst2A was at least 10 times higher
than in naı¨ve PBMCs (10 000–60 000 copies obtained
per million cells), while sst3 expression was comparable
with PBMCs. In transformed B-cell lines both sst2A and
sst3 levels were much higher than in naı¨ve PBMCs
(500 000–800 000 copies obtained per million cells,
i.e. more than 500 and 35 times higher for sst2A and
sst3 respectively).
Finally, we evaluated the expression of CST mRNA in
T- and B-lymphocytes by Q-PCR. T-lymphocytes
expressed CST, and CST mRNA levels were downregu-
lated when the cells were incubated with PHA
(Fig. 6A). CST expression in B-lymphocytes could only
be detected in two out of three donors and in these
two donors we found an upregulation after 24 h of cul-
ture. However, when the cells were cultured for 24 h
with addition of PHA, CST levels returned to basal
levels (Fig. 6B).
Fluo-SS ligand binding to monocytes
To confirm that, besides sst mRNA, the protein could
also be detected as ligand-binding sites, we performed
FACS analysis on cell populations of naı¨ve PBMCs,
PHA-activated non-adherent PBMCs (i.e. enriched for
T- and B-lymphocytes) and on LPS-activated Percoll
gradient-isolated monocytes (purity 70–90%). The
purity of monocytes was determined by FACS analysis,
using CD14, CD68, CD71, CD26, CD1a, CD80, CD86
and HLADR antibodies (data not shown). The cells of
the purified monocyte fraction were positive for CD14,
CD26, CD71, CD86 and HLA-DR (70 –90%), in agree-
ment with the CD-marker expression pattern of mono-
cytes (35). Using the fluorescent SS14 analogue we
were able to detect sst only in the activated mono-
cyte-enriched cell population, but not in the naı¨ve
PBMC fraction or in the activated non-adherent
PBMC fraction. The signal was specific for SS because
it was displaced by addition of excess unlabelled SS14
analogue (Fig. 7).
Discussion
In the present study we have determined for the first
time unequivocally that only sst3 is expressed at signifi-
cant levels in human PBMCs, resembling the in vivo
situation as closely as possible. This expression is
found in B-lymphocytes, as well as in T-lymphocytes,
but not in monocytes. Expression of sst3 mRNA in
B-lymphocytes was significantly lower compared with
the expression of this sst in T-lymphocytes. Freshly iso-
lated monocytes derived from peripheral blood do not
express any of the five sst, but upon activation these
cells were shown to express sst2A mRNA. Previously,
Figure 4 Expression of sst3 mRNA in T-lymphocytes. This figure
represents the expression of sst3 mRNA in T-lymphocytes. sst3
mRNA levels were corrected for hprt levels and bars represent
the percentage of upregulation compared with control cells.
Expression levels of sst3 mRNA were evaluated in freshly isolated
T-lymphocytes (control), in T-lymphocytes after 24 h of culture
(24 hr) and after 24 h of culture with addition of PHA
(24 hr þ PHA). Results are the mean of three independent
experiments using cell samples from three different donors.
*P , 0.01 when compared with control.
Figure 5 Expression of sst2A and sst3 mRNA in human immune
cells and cell lines. sst2A and sst3 levels were corrected for the
amount of hprt detected in each sample and are given in arbitrary
units. (A) Expression of sst2A in cell suspensions from normal
human thymocytes (n ¼ 2), normal human bone marrow (n ¼ 2),
acute myeloid leukaemia (AML) cells (n ¼ 2), established T-lym-
phoid cell lines Jurkat, HPB-ALL and Peer, and two EBV-trans-
formed B-cell lines. (B) Expression of sst3 mRNA was evaluated
in the same preparations. nd ¼ not detected.
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we demonstrated that monocytes, after a Ficoll and
Percoll density-gradient centrifugation, express a very
low amount of sst2A mRNA (36). This suggests that
already minimal activation, caused by the Percoll den-
sity-gradient centrifugation step, of the cells results in
upregulation of sst2A mRNA. Stimulation of T- and B-
lymphocytes with non-specific mitogens did not alter
the expression pattern of receptor subtypes. SS mRNA
was undetected in all cell populations studied, whereas
we detected CST mRNA in lymphocytes. In a previous
study we demonstrated expression of the SS-like peptide
CST in monocytes and its functionally derived cells, i.e.
macrophages and dendritic cells (36). Since the sensi-
tivity of our assay was set at detection of expression
in approximately 10% of the cell population, it is not
known whether all T- and B-lymphocytes express sst3,
or whether sst3 expression is restricted to a subset of
the T- and B-lymphocytes. Separation of T-lymphocytes
into the major subpopulations of CD4þ T-helper cells
and CD8þ cytotoxic T-cells showed sst3 mRNA to be
present in both. Using Fluo-SS derivative in FACS ana-
lysis we were not able to detect sst on the T- or B-lym-
phocyte populations. This could suggest that the
expression of sst3 in these cells is very low or restricted
to a very minor subset of the lymphocytes or, alterna-
tively, that the Fluo-SS derivative has altered specificity
for sst3. Moreover, previous studies have demonstrated
that in the cerebellum high levels of sst3 receptors
could be detected, while radioligand-binding studies
failed to detect sst3-binding sites in this region (37,
38). Recent studies have shown that sst can form
either homo- or heterodimers with other sst or other
G-protein coupled receptors (39, 40). Heterodimeriza-
tion of sst3 with sst2 resulted in a 100-fold lower affinity
for sst3-selective agonists, compared with cells selec-
tively expressing sst3 (39). However, heterodimerization
of sst3 with other sst can be ruled out in lymphocytes,
as no other sst are expressed. Therefore, heterodimeri-
zation with other members of the G-protein coupled
receptor family might provide a potential explanation
for the difficulty in detecting sst3-binding sites in our
studies. Further studies will have to elucidate this issue.
A number of studies have shown functional effects of
SS on human lymphocytes (6, 20, 41, 42), providing
evidence for the presence of functional sst on these
cells. Corroborating our data, sst3 was recently shown
to be present in human enriched lymphocyte fractions,
which also contained functional SS-binding sites (43).
Our data obtained with Q-PCR on PBMC samples
reveal that the number of sst3 cDNA copies obtained
per million cells is approximately 15 000 or less.
Assuming that the combined efficiency of RNA isolation
and cDNA synthesis is in the order of 10%, this suggests
that only a subpopulation of the T-lymphocytes (which
comprise more than 50% of the PBMC population)
express sst3.
Freshly isolated monocytes do not express sst2A or
sst3 at detected levels, but can be induced to express
sst2A receptor mRNA. The presence of sst on these acti-
vated monocytes was confirmed using Fluo-SS and
FACS analysis. Any of the non-specific stimuli we
applied was sufficient to trigger this induction.
Expression of sst2A was in some samples detectable as
early as 1 h after stimulation. These observations
suggest that sst2A upregulation is a very early event
in activation of monocytes. By Q-PCR we showed that
the level of sst2A induction varies among different
donors, but that it is very substantial in all cases.
Translating our results with naı¨ve and in vitro-acti-
vated immune cells from the peripheral circulation to
the situation for immune cells present in lymphatic tis-
sues, it seems very likely that the receptor-binding sites
found with radiolabelled SS (analogues) are present on
immune cells from the monocytic lineage. Whether the
lymphocytes after migration into the tissues also express
sufficient amounts of sst to be visualized in autoradiog-
raphy is uncertain, since T-lymphocyte-rich regions in
lymphoid tissues were reported to be sst negative and
Figure 6 Expression of CST mRNA in human B- and T-lympho-
cytes. Expression of CST mRNA was determined in unstimulated
cells (control), after 24 h of culture (24 hr) and after 24 h of culture
with addition of PHA (24 hr þ PHA). (A) Expression of CST
mRNA in T-lymphocytes (mean of three donors). *P , 0.001
when compared with control cells. (B) Expression of CST mRNA
in B-lymphocytes (mean of two donors). Bars represent the
percentage of upregulation when compared with control.
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germinal centres of secondary lymphatic follicles rich in
B-lymphocytes were shown to be receptor positive by
autoradiography (10, 44). Our recent studies using a
sst2A-specific antibody for immunohistochemistry con-
firmed the presence of the sst2A receptor on cells of the
monocytic lineage and the absence of this receptor
from T-lymphocytes in human rheumatoid synovium
(13) and sarcoid granuloma tissue biopsies (12). How-
ever, we cannot rule out the possibility that one or
more of the receptor subtypes is upregulated by other,
more specific stimuli than the ones we applied. Further-
more, cells other than lymphocytes or monocytes/
macrophages in lymphoid tissues are likely to express
SS and sst as well, such as has been shown in endothelial
cells in inflammatory lesions (13) and in thymic
epithelial cells from normal human thymus (31).
Knowing these results, we may now understand
much better the data described so far in the literature.
Whether or not sst were detected in PBMCs presumably
depended on the extent to which monocytes were acti-
vated during isolation of the PBMCs (17 –19). More-
over, our results show that sst mRNA expression in
established cell lines may not necessarily be representa-
tive for human immune cells in vivo. Most of the lym-
phoid cell lines studied by Tsutsumi et al. (19)
expressed mRNA for sst2 – 5, with sst2 being the major
subtype. Our own studies of a panel of lymphoid cell
lines revealed only sst2A and sst3 or no SS receptor
expression at all (26, 45). The incongruity possibly
can be explained by differences in assay sensitivity.
Nevertheless, it is evident that many lymphoid cell
lines express sst2A as the major subtype, which is
Figure 7 FACS analysis of Fluo-SS binding to T- or B-lymphocytes or to monocytes. Naı¨ve PBMCs or an enriched lymphocyte popu-
lation cultured for 24 h in the presence of PHA were labelled with Fluo-SS and PE-conjugated CD3 or CD19 antibodies to analyse bind-
ing of SS to T- and B-lymphocytes respectively. Monocytes were analysed by labelling the naı¨ve PBMCs with Fluo-SS and PE-
conjugated CD14 antibody and by labelling an enriched monocyte population cultured for 24 h in the presence of LPS with Fluo-SS.
The grey areas represent the fluorescent signal remaining after displacement of Fluo-SS by unlabelled SS, the solid line shows the
amount of fluorescence after labelling with Fluo-SS. These data are examples of one of the experiments carried out and represent the
data found in three independent healthy donors.
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certainly at variance with lymphoid cells in the circula-
tion. Our comparison of human PBMCs and human
lymphoid cell lines also revealed that in immortalized
cell lines the expression level of sst2A is similar to or
much higher than in activated PBMCs. Since also the
amount of hprt RNA per cell was much higher in the
cell lines than in PBMCs, presumably due to
the enhanced proliferative capacity of the immortalized
cells, the absolute numbers of sst2A and sst3 mRNA
copies per cell are 10- to 800-fold higher in the immor-
talized cell lines.
Results reported in studies concerning the function of
SS and its receptors in immune cells are not conclusive
as to which sst mediate the different effects. On the
other hand, expression of sst2 receptors has been
found to be of major interest in the treatment of patients
with growth hormone-secreting pituitary adenomas,
carcinoids and other gastroenteropancreatic tumours
(46–48). Treatment of these patients with SS ana-
logues has demonstrated an improvement of clinical
symptoms due to the inhibition of the secretion of hor-
mones or bioactive peptides by the tumour cells (48). In
addition, reduction of tumour mass has been observed
in selected cases. Apart from their important role in
therapy, sst can also play a role in diagnosis of disease.
Radiolabelled SS analogues are used for visualization of
neuroendocrine tumours (49), but also, diseases invol-
ving cells of the human immune system, like Hodgkin’s
and non-Hodgkin’s lymphomas and sarcoidosis, can be
visualized by a gamma camera after binding of radio-
labelled SS analogues to sst2 receptors present in
affected tissues in these diseases (16, 50, 51). These
studies have thus shown that sst can play a major
role in diagnosis and therapy of various diseases.
In vitro culturing of human PBMCs has demonstrated
effects of SS or its analogues on numerous (immune)
functions of these cells. However, several conflicting
results regarding effects of SS (or its analogue octreo-
tide) on proliferation, differentiation or cytokine pro-
duction have been reported (discussed below), which
possibly can be attributed to different experimental
designs but do not clarify the function of SS in the
immune system.
sst2A receptors are usually associated with inhibition
of hormone secretion (52, 53). Also, for LPS-activated
human monocytes, it has been shown that SS inhibits
the secretion of pro-inflammatory cytokines (54),
although another study reported stimulation of
secretion (55). Notwithstanding these conflicting
accounts, the biological significance of the early induc-
tion of sst2A during activation of monocytes might be
that through this receptor the inflammatory response
could be modulated (decreased) immediately it is
invoked. The presence of SS-binding sites in rheumatoid
arthritis or in granulomatous diseases (15, 16, 25) and
the effects of SS in arthritis (56) also suggest that SS may
act in inflammation. Consistent with the suggestion that
sst2A could mediate these effects are our recent studies
demonstrating the presence of sst2A by immunohisto-
chemistry in cells of the monocytic lineage in human
rheumatoid synovium and sarcoid granulomas (12, 13).
The identification of SS-binding sites in haematologi-
cal malignancies and the ability of SS (or octreotide) to
inhibit proliferation of these malignant cells in vitro (18,
57) hints at a role for SS in the regulation of prolifer-
ation and/or differentiation during haematopoiesis.
The presence of sst2A in normal human bone marrow
cells, where differentiation and proliferation take
place, as well as in tumour cells from haematological
origin might suggests that sst2A is involved in regulat-
ing the balance between proliferation and differen-
tiation. Moreover, recent studies have shown that SS,
acting via sst2, induces migration of human haemato-
poietic progenitor cells (58). These findings suggest
that sst2 on human immune cells may play a role in
homing of the cells during differentiation or in
immune reactions by chemotaxis.
In human PBMCs, inhibition of proliferation of mito-
gen-activated lymphocytes has been reported (20, 41,
42), although contrasting results have also been
obtained with enriched lymphocyte fractions (43) and
with a lymphoid cell line (22). In the latter studies pro-
liferation could be stimulated by SS. Because lympho-
cytes selectively express sst3 mRNA, we suggest that
this receptor subtype mediates the responses observed
in this cell type. Interestingly, sst3 has been shown to
be involved in SS-induced apoptosis, resulting in
growth inhibition of the cell population (59). Our finding
that sst3 is the main subtype expressed in mature lym-
phocytes and, moreover, the upregulation of sst3
mRNA in T-lymphocytes during culture and by acti-
vation with PHA, suggests that this receptor subtype
may have an important function in these cells. Mature
B- and T-lymphocytes in the circulation are resting
cells that start proliferation after activation. It is there-
fore conceivable that in mature B- and T-lymphocytes
sst3 may have an important function in regulating the
balance between proliferation and apoptosis after acti-
vation. However, with respect to the possible role of
sst3 in mature B-lymphocytes we could only detect sst3
mRNA by RT-PCR, and not by Q-PCR. This suggests
that sst3 mRNA expression in B-lymphocytes is very
low and therefore it may be hypothesized that sst3 in
B-lymphocytes plays a less important regulatory role,
when compared with T-lymphocytes, in which we
found clear regulation of sst3 mRNA expression.
Equally important for the understanding of the func-
tion of SS and its receptors in lymphoid tissues is knowl-
edge of which cells produce the agonistic peptide SS. We
demonstrated that PBMCs do not synthesize SS mRNA,
not even after activation. We therefore assume that SS
is synthesized in other cells in the lymphoid tissues, e.g.
in thymic epithelial cells (31) or in nerve endings, or per-
haps in endothelial cells. Another possibility is that lym-
phocytes or monocyte-derived cells do express SS mRNA
after more specific stimulation in vivo, conceivably after
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migration from the periphery into lymphoid tissues or to
sites of inflammation. On the other hand, the detection of
CST mRNA in various tissues and cells of the human
immune system (27) and the detection of CST mRNA
in the present study in T- and B- lymphocytes may
suggest that CST, rather than SS, may play a regulatory
role acting via the sst in these immune cells. However, in
monocytes, macrophages and dendritic cells, CST mRNA
was upregulated upon activation with LPS (27), whereas
in B- and T-lymphocytes we found in general a downre-
gulation of the CST mRNA expression upon activation.
The significance of this downregulation in T- and B-lym-
phocytes as well as the functional significance of CST in
these cells remains to be determined. We hypothesized
that the downregulation of endogenous CST expression
may be a direct feedback mechanism following the upre-
gulation of sst3, in order to regulate responsiveness to the
peptide. This suggests that CST and sst3 may interact in
regulation of the number of T-cells. Although we have
now extensively demonstrated the expression of different
sst and their ligands in cells of the human immune
system in vitro, the functional significance of SS and its
receptors in the human immune system in vivo remains
largely unknown. As discussed above, previous studies
have shown different (conflicting) results. Further
studies will have to demonstrate the functional signifi-
cance of SS or SS-like peptides and their receptors in
vivo and the potential implications for treatment of
immunological diseases.
Summarizing, we have shown for the first time that
human B- and T-lymphocytes in the peripheral blood
selectively express sst3, whereas circulating monocytes
do not express sst. Expression of sst3 mRNA can be upre-
gulated by activation in T-lymphocytes, while sst3
expression levels in B-lymphocytes are probably very
low, suggesting a less important role of these receptors
in B-lymphocytes, when compared with T-lymphocytes.
Upon stimulation with non-specific mitogens the mono-
cytes, but not the lymphocytes, are induced to express
sst2A receptors. No expression of SS mRNA was detected,
not even after stimulation. In line with the expression of
CST mRNA in monocytes, macrophages and dendritic
cells, CST mRNA is expressed in T- and B-lymphocytes
as well. The differential and cell-type-specific regulation
of the expression of sst2A and sst3 receptors in human
PBMC, in combination with data on functional studies
of SS on immune cells, suggests that the function of
SS, or more presumably CST, and its receptors in the
human immune system may be found in regulating
cytokine secretion in inflammatory responses and in
regulating the balance of proliferation and apoptosis of
(activated) lymphocytes in immune responses.
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